SAN ANTONIO (EGMN) - An investigational genetic test may not only be able to differentiate women likely to have early recurrence of estrogen receptor-positive breast cancer but also could lead to novel combinations of existing drugs to treat these patients earlier in the disease process, according to Dr. Minetta C. Liu.Researchers developed a 91-gene classifier "that essentially separated those patients who were going to recur early [within 3 years] vs. those who were going to recur late [beyond...